C-suite barometer: life sciences & pharmaceuticals sector view

Drawing on insights from executives from across more than 35 countries, our latest report captures how sector players are navigating complexity, investing in growth, and positioning themselves for long-term success in a competitive landscape.

Featuring commentary from our Forvis Mazars experts and contributors including Damien Catoir, Servier, and Cédric Moreau, Sofinnova Partners, the report provides a valuable benchmark for sector players looking to navigate a rapidly evolving landscape.

Key findings 

• 96% report growth, with a clear majority also boasting growing revenues, eleven points higher than others globally.
• 55% of C-suite executives cite increased competition and 47% cite supply chain restrictions as the top factors holding back growth.
• 39% of leaders identify economic factors as having the biggest impact on businesses, with 37% viewing the emergence of technologies as significant.
• 67% of firms in the sector are boosting investment, averaged across all business activities

Looking ahead, executives have outlined three core strategic priorities for 2025 and beyond: entering new products and services, accelerating digital transformation to enhance efficiency and agility, international expansion, and strengthening supply chains in response to geopolitical and climate risks- particularly sustainability and supplier responsibility- into core business strategy.

Explore the full findings and discover how sector leaders are preparing for growth in a complex and competitive environment.